STATUTORY INSTRUMENTS

2020 No. 1348

The Reciprocal and Cross-Border Healthcare (Amendment etc.) (EU Exit) Regulations 2020

PART 4

Amendment of Northern Ireland Cross-Border Healthcare Regulations

Substitution of regulation 19

17. For regulation 19 substitute—

"The Health and Personal Social Services (General Medical Services Contracts) (Prescription of Drugs Etc) Regulations (Northern Ireland) 2004

19.—(1) The Health and Personal Social Services (General Medical Services Contracts) (Prescription of Drugs Etc) Regulations (Northern Ireland) 2004(1) are amended as follows.

(2) In Schedule 2 (drugs, medicines and other substances that may be ordered only in certain circumstances), in the entry in column 2 of the table relating to patients with erectile dysfunction—

- (a) for sub-paragraph (b) (including the "or" at the end) substitute—
 - "(b) a man who is a national of an EEA State who—
 - (i) immediately before IP completion day was entitled to treatment by virtue of Article 7(2) of Council Regulation 1612/68 as extended by the EEA Agreement or was entitled to treatment by virtue of any other enforceable EU right;
 - (ii) has erectile dysfunction and was on 14th September 1998 receiving a course of treatment under a national health insurance system of an EEA State for that condition with any of the drugs listed in subparagraph (a); and
 - (iii) immediately before IP completion day was receiving a course of treatment for the condition mentioned in paragraph (ii) of this subparagraph with any of the drugs listed in sub-paragraph (a); or";
- (b) for sub-paragraph (c) (including the "or" at the end) substitute—
 - "(c) a man who is not a national of an EEA State but who is the member of the family of such a national and who—
 - (i) immediately before IP completion day had an enforceable EU right to be treated no less favourably than the national in the provision of medical treatment;

(1) S.R. 2004 No. 142; relevant amendments were made by S.R. 2011 No. 327 and 2014 No. 215.

- (ii) has erectile dysfunction and was on 14th September 1998 receiving a course of treatment for that condition with any of the drugs listed in sub-paragraph (a); and
- (iii) immediately before IP completion day was receiving a course of treatment for the condition mentioned in paragraph (ii) of this subparagraph with any of the drugs listed in sub-paragraph (a); or".".